A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples